GlassScriptPhysician profile
Adam Deutsch
NPI 1275532533
$1,908.93
in general payments reported to CMS, 2019-2025
21 companies · $77.45 in 2025
The $77.45 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $130 · 2021: $208 · 2022: $137 · 2023: $425 · 2024: $593 · 2025: $77.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $354.51 | 2019-2024 | |
| Amgen INC. | $352.44 | 2019-2025 | Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $135.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $109.87 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $107.46 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $105.70 | 2024 | Arcalyst |
| Pfizer INC. | $89.33 | 2019-2025 | |
| Novo Nordisk INC | $87.71 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $85.93 | 2019-2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $78.06 | 2022-2024 | Quviviq |
| Lexicon Pharmaceuticals, INC. | $70.97 | 2024 | |
| Abbott Laboratories | $65.26 | 2021-2023 | Jot Dx |
| Heartflow, INC. | $53.48 | 2023-2025 | Ffrct |
| Esperion Therapeutics, INC. | $41.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.35 | 2023 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.93 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.72 | 2019 | |
| Lilly USA, LLC | $23.62 | 2023 | Mounjaro |
| Althera Pharmaceuticals LLC | $20.02 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.01 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Deutsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.